NEW
YORK, Jan. 12,
2015 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz &
Grossman, LLC is investigating potential claims against the Board
of Directors of NPS Pharmaceuticals Inc. ("NPS Pharmaceuticals" or
the "Company") (Nasdaq:NPSP) related to the proposed acquisition of
the Company by Shire
PLC. The
transaction is valued at around $5.2
billion or $46.00 per
share.
This investigation concerns whether the Board of
Directors of NPS Pharmaceuticals breached their fiduciary duties to
stockholders by failing to adequately shop the Company before
agreeing to enter into the proposed transaction, and whether the
Company has disclosed all material information to shareholders
about the transaction
If you are aware of any facts relating to this
investigation, or own shares of NPS Pharmaceuticals, you can assist
this investigation by contacting either Peretz Bronstein or his Investor Relations
Coordinator Eitan Kimelman of
Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via
email
info@bgandg.com. Those who
inquire by e-mail are encouraged to include their mailing address
and telephone number.
Bronstein, Gewirtz &
Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive
pursuit of litigation claims on behalf of our
clients. In addition to representing institutions
and other investor plaintiffs in class action security litigation,
the firm's expertise includes general corporate and commercial
litigation, as well as securities
arbitration. Attorney advertising. Prior
results do not guarantee similar outcomes.
Contact:
Bronstein,
Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-nps-pharmaceuticals-inc-concerning-its-proposed-sale-to-shire-plc-npsp-300019016.html
SOURCE Bronstein, Gewirtz & Grossman, LLC